Aripiprazole
- Generic Name
- Aripiprazole
- Brand Names
- Abilify, Aripiprazole Mylan Pharma (previously Aripiprazole Pharmathen), Abilify Maintena, Aripiprazole Accord, Aripiprazole Sandoz, Aripiprazole Zentiva
- Drug Type
- Small Molecule
- Chemical Formula
- C23H27Cl2N3O2
- CAS Number
- 129722-12-9
- Unique Ingredient Identifier
- 82VFR53I78
- Background
Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects through agonism of dopaminergic and 5-HT1A ...
- Indication
Aripiprazole is indicated for the treatment of acute manic and mixed episodes associated with bipolar I disorder, irritability associated with autism spectrum disorder, schizophrenia, and Tourette's disorder. It is also used as an adjunctive treatment of major depressive disorder.[L45859 An injectable formulation of aripiprazole is indicated for agitation as...
- Associated Conditions
- Agitation, Bipolar 1 Disorder, Irritability, Major Depressive Disorder (MDD), Mixed manic depressive episode, Psychosis, Psychotic Depression, Schizophrenia, Tourette's Disorder (TD), Acute Manic episode
- Associated Therapies
- Monotherapy
Safety and Efficacy of Aripiprazole and Ziprasidone Among Schizophrenic Patients With Metabolic Syndrome
- First Posted Date
- 2012-10-25
- Last Posted Date
- 2012-11-27
- Lead Sponsor
- University of Malaya
- Target Recruit Count
- 175
- Registration Number
- NCT01714011
- Locations
- 🇲🇾
University Malaya Medical Centre, Kuala Lumpur, Malaysia
Potentiation of Quetiapine Treatment With Lithium or Aripiprazole in Bipolar 1 Nonresponders Patients
- First Posted Date
- 2012-10-19
- Last Posted Date
- 2012-10-19
- Lead Sponsor
- University of Sao Paulo
- Target Recruit Count
- 50
- Registration Number
- NCT01710163
- Locations
- 🇧🇷
Institute of Psychiatry, University of São Paulo, São Paulo, Brazil
🇧🇷Institute of Psychiatry, São Paulo, Brazil
Open-label Study to Evaluate the Effectiveness of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Bipolar I Disorder
- First Posted Date
- 2012-10-19
- Last Posted Date
- 2018-09-21
- Target Recruit Count
- 748
- Registration Number
- NCT01710709
Canadian Biomarker Integration Network for Depression Study
- Conditions
- Interventions
- First Posted Date
- 2012-08-02
- Last Posted Date
- 2018-05-11
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 211
- Registration Number
- NCT01655706
- Locations
- 🇨🇦
University of British Columbia, Vancouver, British Columbia, Canada
🇨🇦University Health Network, Toronto, Ontario, Canada
🇨🇦University of Calgary, Calgary, Alberta, Canada
A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With Autistic Disorder
- First Posted Date
- 2012-06-12
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 86
- Registration Number
- NCT01617460
A Short Treatment Study of Aripiprazole in Pediatric Patients With Autistic Disorder
- Conditions
- Interventions
- First Posted Date
- 2012-06-12
- Last Posted Date
- 2017-04-11
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 92
- Registration Number
- NCT01617447
A Study to Compare Capillary and Venous Whole Blood and Plasma Concentrations of Five Antipsychotics
- Conditions
- Interventions
- First Posted Date
- 2012-05-30
- Last Posted Date
- 2013-04-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 31
- Registration Number
- NCT01607762
Change in Brain Metabolism and Cognitive Function by Aripiprazole
- Conditions
- First Posted Date
- 2012-03-26
- Last Posted Date
- 2012-03-26
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 15
- Registration Number
- NCT01562808
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
An Observational Drug Utilization Study of Asenapine in the United Kingdom (P08308)
- First Posted Date
- 2011-12-23
- Last Posted Date
- 2022-02-04
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 42
- Registration Number
- NCT01498770
RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder
- Conditions
- Interventions
- First Posted Date
- 2011-12-12
- Last Posted Date
- 2015-01-26
- Lead Sponsor
- Reviva Pharmaceuticals
- Target Recruit Count
- 234
- Registration Number
- NCT01490086
- Locations
- 🇲🇾
Reviva Site, Ridzuan, Malaysia
🇵🇭Reviva site, Subangdaku, Philippines
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.